What has Stemline Therapeutics’ lead compound got that investigational treatments from Merck Sharp & Dohme, Zogenix and Advicenne Pharma haven’t?
Stemline Has What It Takes On EU Fast-Track Front
There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.
